2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases: Effect of odanacatib on bone mineral density and estimated bone strength in postmenopausal women: a CT-based substudy of the phase 3 long-term odanacatib fracture trial (LOFT)

A subset of 164 women from the Long-Term Odanacatib Fracture Trial were included in this imaging sub-study to evaluate the effect of odanacatib versus placebo on volumetric bone mineral density (vBMD) of the lumbar spine and total hip. Follow-up was made at 24 months of treatment, and percent change in trabecular vBMD of the lumbar spine and cortical vBMD of total hip were compared. Results demonstrated a significantly greater mean increase in both outcome measures with odanacatib versus placebo.